Related Experiment Video
Updated: Jun 17, 2026
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Neutralizing antibodies to 500 microg interferon beta-1b: 28-month results of the IDEAS extension trial
M H Gottesman1, S Friedman-Urevich, E Boylan
1Winthrop University Hospital, Mineola, New York 11501, USA. mgottes@winthrop.org
Abstract:
The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had previously received the double dose (500 microg) for up to 28 months. Fifteen patients entered the extension trial; five patients were neutralizing antibody-positive at the start of the trial. The present study demonstrates that when neutralizing antibodies develop in patients receiving higher doses of interferon beta-1b they tend to persist for a prolonged period, although neutralizing antibody titers tend to decrease over time and some patients may revert to neutralizing antibody-negative status.
Insights
Neutralizing antibodies to interferon beta-1b can persist long-term in patients receiving higher doses. While antibody levels may decrease, some patients may become antibody-negative again over time.
Area of Science:
- Immunology
- Pharmacology
- Neurology
Background:
- Interferon beta-1b is used to treat certain conditions.
- Higher doses of interferon beta-1b may increase the risk of antibody formation.
- Monitoring neutralizing antibodies is important for treatment efficacy.
Purpose of the Study:
- To assess the persistence of neutralizing antibodies to interferon beta-1b.
- To evaluate antibody development in patients receiving higher doses.
- To understand the long-term antibody response in patients on interferon therapy.
Main Methods:
- Extension trial design.
- Monitoring of neutralizing antibodies to interferon beta-1b.
- Analysis of antibody status over 28 months in patients on high-dose therapy.
Main Results:
- Neutralizing antibodies, once developed at higher doses, tend to persist.
- Antibody titers generally decrease over the observation period.
- A subset of patients may serorevert to a neutralizing antibody-negative status.
Conclusions:
- Persistent neutralizing antibodies are a consideration in high-dose interferon beta-1b therapy.
- Long-term monitoring reveals a trend towards decreasing titers and potential seroreversion.
- Further research may explore the clinical implications of persistent antibodies.
